NCT01760980View on ClinicalTrials.gov

Pivotal Bioequivalence Study of Exemestane 25 mg Tablets Under Fasting Conditions in Healthy Subjects

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 30, 2012

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions
Healthy
Interventions
DRUG

Reference product (A) Aromasin (Exemestane)

Aromasin tablets will be administered under fasting conditions on two occasions

DRUG

Test product (B) Exemestane

Exemestane tablets will be administered under fasting conditions on one occasion

Trial Locations (1)

9301

Bloemfontein Early Phase Clinical Unit, PAREXEL International (South Africa), Bloemfontein

Sponsors

Lead Sponsor

Actavis Inc.
All Listed Sponsors
lead

Actavis Inc.

INDUSTRY